Etienne-Selloum, N.; Prades, J.; Bello-Roufai, D.; Boone, M.; Sevestre, H.; Trudel, S.; Caillet, P.; Coutte, A.; Desenclos, C.; Constans, J.-M.;
et al. Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. Pharmaceuticals 2021, 14, 882.
https://doi.org/10.3390/ph14090882
AMA Style
Etienne-Selloum N, Prades J, Bello-Roufai D, Boone M, Sevestre H, Trudel S, Caillet P, Coutte A, Desenclos C, Constans J-M,
et al. Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. Pharmaceuticals. 2021; 14(9):882.
https://doi.org/10.3390/ph14090882
Chicago/Turabian Style
Etienne-Selloum, Nelly, Julien Prades, Diana Bello-Roufai, Mathieu Boone, Henri Sevestre, Stéphanie Trudel, Pascal Caillet, Alexandre Coutte, Christine Desenclos, Jean-Marc Constans,
and et al. 2021. "Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma" Pharmaceuticals 14, no. 9: 882.
https://doi.org/10.3390/ph14090882
APA Style
Etienne-Selloum, N., Prades, J., Bello-Roufai, D., Boone, M., Sevestre, H., Trudel, S., Caillet, P., Coutte, A., Desenclos, C., Constans, J.-M., Martin, S., Choulier, L., Chauffert, B., & Dontenwill, M.
(2021). Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. Pharmaceuticals, 14(9), 882.
https://doi.org/10.3390/ph14090882
